Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145219 · ClinicalTrials.gov registry record · Phase 3
House Dust Mite Allergy Trial In Children
A Phase 3 study, sponsored by ALK-Abelló A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,460
- Enrollment target
NCT04145219 is a Phase 3 study that has completed, run by ALK-Abelló A/S. The registered enrollment target is 1,460 participants.
The verdict
NCT04145219, a Phase 3 study, has completed, sponsored by ALK-Abelló A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,460 participants
- Enrollment target
Study Summary
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
Interventions
- OTHER Placebo
- BIOLOGICAL Sublingual allergy immunotherapy tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,460 participants |
| Start Date | 2019-10-12 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145219
The ClinicalTrials.gov registry entry for NCT04145219 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALK-Abelló A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04145219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04145219 about?
NCT04145219 is a clinical study titled "House Dust Mite Allergy Trial In Children". A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
What is the current status of trial NCT04145219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,460 participants. The study started on 2019-10-12. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT04145219?
The interventions under investigation include: Placebo (OTHER), Sublingual allergy immunotherapy tablet (BIOLOGICAL).
Who is sponsoring clinical trial NCT04145219?
This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.